The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Cost-Effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States
Antoine Chaillon1, Adriane Wynn2, Tatyana Kushner3, Nancy Reau4, Natasha K Martin15
Author information
1Division of Infectious Diseases and Global Public Health, University of California San Diego, CA.
2Perelman School of Medicine, University of Pennsylvania, PA.
3Icahn School of Medicine at Mount Sinai, New York.
4Department of Internal Medicine, Rush University Medical Center, IL.
5Population Health Sciences, University of Bristol, UK.
Abstract
To inform proposed changes in U.S. HCV screening guidelines, we assessed the cost-effectiveness of HCV antenatal rescreening for women without evidence of HCV during a prior pregnancy, using a previously published model. Universal HCV rescreening among pregnant women was cost-effective (ICER $6,000/QALY) and should be recommended nationally.